Yahoo

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...
Yahoo

Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial

Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...
Insider Monkey

Jim Cramer on Recursion: “It Is so Low That It Comes in Under the Category of Speculative”

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer discussed, along with the tech battleground. Answering a caller’s query about the stock during the lightning round, Cramer ...
Forbes

Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off. Plus: Stop Hiding Your Wins

This is this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, leaders and investors straight to your inbox. Click here to get on the ...
Forbes

Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
The Motley Fool

Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...
Quanta Magazine

In a First, AI Models Analyze Language As Well As a Human Expert

Among the myriad abilities that humans possess, which ones are uniquely human? Language has been a top candidate at least since Aristotle, who wrote that humanity was “the animal that has language.” ...
Seeking Alpha

Recursion Pharmaceuticals: Recent Gains Are Mysterious Given A Lack Of Overall Progress

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Hosted on MSN

Where Will Recursion Pharmaceuticals Be in 5 Years?

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...